跳至主要内容
临床试验/CTRI/2024/06/068686
CTRI/2024/06/068686招募中4 期

To Evaluate efficacy and tolerability of Vasograin ( Ergotamine 1 mg plus Paracetamol 250 mg plus Prochlorperazine 2.5 mg plus Caffeine 100 mg) in adult patients in the treatment of acute migraine: An Open label, Non-randomized, Single arm Clinical Trial - NI

Cadila Pharmaceuticals Ltd.0 个研究点目标入组 1,000 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Patients of both genders.
  • 2. Age older or equal to 18 years.
  • 3. Patients which are experiencing migraine headache as per physician’s clinical judgement.
  • 4. Ability to understand and consent to participate in this clinical research, expressed by signing the Informed Consent Form (ICF).

排除标准

  • 1. Hypersensitivity to any of the study drugs.
  • 2. Pregnant or lactating females or female using an oral contraceptives.
  • 3. Patients with clinically significant hepatic or renal disease.

研究者

相似试验